Case Report

Pityriasis Lichenoides et Varioliformis Acuta as a Complication of COVID-19 Infection

Henriette De La Garza 1, *, Elie Saliba 1,2, *, Monica Rosales Santillan 3, Candice Brem 1 and Neelam A. Vashi 1,3, *

1 Department of Dermatology, Boston University School of Medicine, Boston, MA 02118, USA; hadelaga@bu.edu (H.D.L.G.); elie_saliba@brown.edu (E.S.); mrosales@bu.edu (M.R.S.); candice.brem@bmc.org (C.B.)
2 Department of Dermatology, Brown University, Providence, RI 02903, USA
3 Boston Health Care System, U.S. Department of Veterans Affairs, Boston, MA 02130, USA
* Correspondence: nvashi@bu.edu
† These authors contributed equally to this work.

Abstract: Pityriasis lichenoides is an acute and/or chronic skin disease associated with recurrent erythematous papules that self-resolve. While its etiology is unknown, preceding viral infection may play a role. We present an atypical case of a 40-year-old woman with pityriasis lichenoides et varioliformis acuta as a complication of a COVID-19 infection.

Keywords: pityriasis lichenoides; pityriasis lichenoides et varioliformis acuta; PLEVA; rash; azithromycin; CD30; COVID-19

1. Introduction

Pityriasis lichenoides consists of a group of inflammatory skin disorders that includes both pityriasis lichenoides et varioliformis acuta (PLEVA) and pityriasis lichenoides chronica (PLC) [1].

PLEVA manifests as an acute eruption of small, erythematous to brown macules that rapidly develop into papules with overlying hemorrhagic crust while PLC has a more gradual manifestation of smaller red to brown flat maculopapules with an overlying scale. Both PLEVA and PLC follow a relapsing course with long periods of remission [1–3]. While the etiology of pityriasis lichenoides is unknown, it has been postulated to be a response to foreign antigens such as infectious agents and drugs [2].

2. Case

A 40-year-old woman presented with a 2-month history of new pruritic lesions initially appearing on the trunk then spreading to the face and extremities. Her past medical history was significant for hypothyroidism treated with Levothyroxine. The patient did not report any drug allergies, medication changes, or similar signs in other family members. A review of systems was also negative for fever, chills, nausea, vomiting, or significant weight changes. She was initially prescribed a 60 mg prednisone taper over the course of 4 weeks and topical clobetasol ointment, but she did not note any improvement in her lesions.

On physical examination, there were several erythematous papules, some with overlying hemorrhagic crust or clear fluid vesicles, in different stages of healing located on the face, trunk, and upper and lower extremities. No mucosal findings were seen (Figure 1).

Laboratory workup for HIV, syphilis, group A streptococcus, and infectious mononucleosis were negative. However, she stated that 2 weeks before the appearance of the skin lesions, she had a positive PCR COVID-19 test and a negative COVID vaccination history.
Multiple serial biopsies from both acute and chronic lesions were obtained. The acute lesions demonstrated spongiotic vesiculation and reticular degeneration (Figure 2A,B) while the chronic lesions exhibited more epidermal hyperplasia with overlying parakeratosis containing neutrophils in the stratum corneum (Figure 2C,D). Changes suggestive of PLEVA, such as necrotic keratinocytes, basal layer vacuolization, extravasated red blood cells, and lymphocytic exocytosis, were present in most biopsies (Figures 2 and 3). The dermal infiltrate was predominantly composed of CD3 (+) T-lymphocytes admixed with rare CD20 (+) B-cells. In addition, a few of the biopsies also demonstrated scattered predominant intraepidermal CD30 (+) cells (Figure 3). A monoclonal TCR-γ gene rearrangement was also detected in one of the specimens. The histologic differential diagnosis included PLEVA and lymphomatoid papulosis (LyP).
Figure 3. (A) Spongiotic vesiculation, reticular degeneration, and a wedge-shaped, moderately dense superficial perivascular lymphocytic infiltrate (H & E, 40×). (B) Higher power demonstrates basal layer vacuolization, lymphocytic exocytosis, and extravasated red blood cells (H & E, 200×). (C) Immunoperoxidase staining reveals the lymphocytic infiltrate to be composed of CD3 (+) T cells (80×) with (D) an intraepidermal population staining with CD30 (80×).

Treatment with azithromycin 500 mg on day 1 followed by 250 mg daily until day 5 was initiated. This regimen was repeated every two weeks. The patient noticed slight improvement after 1 week of treatment (Figures 4 and 5). At 5 months follow-up, with continued azithromycin every 2 weeks in addition to triamcinolone 0.1% cream daily, she had marked improvement of the rash with complete resolution of the vast majority of lesions and scattered postinflammatory hyper- and hypopigmentation.

Based on the clinical, histopathologic findings and response to treatment, the patient was diagnosed with PLEVA possibly developing as a complication of a COVID-19 infection.

Figure 4. (A) Abdomen before medical management; (B) after azithromycin initiation.
Figure 5. (A) Lower extremities before medical management; (B) after azithromycin initiation.

3. Discussion

PLEVA manifests as an acute eruption of small, erythematous to brown or purpuric macules that rapidly develop into papules with overlying hemorrhagic crust. The eruption, often involving the trunk and extremities, is polymorphic with lesions at different stages of evolution, varying in severity and temporal development. While it is generally asymptomatic, burning or pruritus may be present. The lesions may also spontaneously resolve with secondary postinflammatory hyper- or hypopigmentation [1,2].

The pathogenesis of PLEVA is unclear. Current theories include infectious etiologies with pathogenic culprits including human immunodeficiency virus, human herpesvirus 7, varicella zoster virus, Epstein–Barr virus, cytomegalovirus, and parvovirus B19 [2,3]. Several reports have described unique presentations of PLEVA characterized by a CD30 (+) component and clonal TCR–γ gene rearrangement in the setting of viral infection [4–8]. Our case similarly demonstrated a CD30 (+) infiltrate and a positive TCR–γ gene rearrangement study. Recently, 11 patients with PLEVA induced by a COVID-19 infection [9,10] and 7 by the COVID-19 vaccine [11–17] have been reported in the literature (Table 1). In the setting of a recent COVID-19 infection, these findings suggest that COVID-19 should likely be added to the list of possible viral agents capable of inducing PLEVA.

On the contrary, some consider PLEVA as a type of cutaneous lymphoproliferative disorder showing overlapping features with mycosis fungoides (MF) and lymphomatoid papulosis (LyP) [7]. In one study, a clonal TCR–γ gene rearrangement was reported in 65% of cases [8]. Additionally, while generally considered an inflammatory condition, some authors have noted various patients with pityriasis lichenoides preceding diagnoses of classic mycosis fungoides or Hodgkin lymphoma and other patients with self-healing lesions resembling PLC coexisting with mycosis fungoides. These authors postulate that the so-called “lymphomatoid” pityriasis lichenoides may exist on a spectrum or continuum with both MF and LyP [18,19].

Histopathological evaluation of PLEVA usually reveals epidermal spongiosis, mild to moderate acanthosis, parakeratosis, dyskeratosis, and occasional vacuolar degeneration with intraepidermal vesicles. The dermis usually shows edema, a dense and diffuse inflammatory infiltrate composed of CD8 (+) T-lymphocytes along the basal layer of the epidermis with prominent lymphocytic exocytosis into the epidermis. Advanced findings usually encountered in febrile ulceronecrotic Mucha–Habermann disease may show an
extension of the inflammatory infiltrate into the epidermis, extravasation of erythrocytes, widespread epidermal necrosis, and nuclear debris in necrotic areas [1,2]. Histopathological examination of our patient showed features such as vacuolar degeneration of the basal layer with necrotic keratinocytes and dense deep periglandular lymphocytic infiltration, which have been consistently described in COVID-19-related dermatosis [20].

| Reference       | Infection/Vaccine | Histopathology                                                                 | Cutaneous Lesions                                       |
|-----------------|-------------------|--------------------------------------------------------------------------------|---------------------------------------------------------|
| Durusu et al. [10] | COVID-19 infection | Hyperkeratosis; irregular acanthosis; focal spongiosis; lymphocytic exocytosis in the epidermis; and band-like lymphohomocytic infiltrate and melanophages in the superficial dermis. | Erythematous to purple lichenoid papules and plaques and hemorrhagic crusts. |
| Gianotti et al. [9] | COVID-19 infection | Dermal lymphocytic infiltrate; interstitial eosinophils; diffuse interface dermatitis; and scattered necrosis of keratinocytes. | Erythematous and purpuric hemorrhagic papules with crusts. |
| Sechi et al. [14] | 2nd dose Pfizer vaccine | Focal epidermal ulceration; spongiosis; parakeratosis; and interface inflammation within a wedge-shaped dermal inflammatory cell infiltrate. | Scattered, nonfolliculocentric papules with erythematous, raised borders and an eroded center, covered by a hemorrhagic crust. |
| Sernicola et al. [12] | 1st dose Pfizer vaccine | Hyperkeratosis; epidermal hyperplasia; diffuse spongiosis with a foci of mixed, lympho-monocytic infiltrates; Langerhans cells; granulocytes; and a dense, polymorphic inflammatory infiltrate in the dermis. | Erythematous-pinkish papular lesions partially covered by sero-hematic crusts. |
| Palmén et al. [11] | 1st dose Pfizer vaccine | N/A | Erythematous, ulcerative, and crusting lesions. |
| Dawoud et al. [13] | 1st dose Pfizer vaccine | Parakeratosis; moderate spongiosis and focal vacuolar alteration of the basal cell layer; mild edema; extravasated red cells; and superficial and deep dermal perivascular, lymphocytic infiltrate. | Erythematous and purpuric hemorrhagic papules with crusts. |
| Filippi et al. [17] | 1st dose AstraZeneca vaccine | Parakeratosis; mild spongiosis; wedge-shaped perivascular lymphocytic infiltrate; and apoptotic keratinocytes and extravasated erythrocytes in the papillary dermis. | Erythematous and erythematous-crusted papules. |

The major histologic differential diagnosis to consider is lymphomatoid papulosis (LyP). Generally, the degree of cytologic atypia in lesions of LyP is more severe and extensive than would be expected in PLEVA. CD30 has been considered by some authors as one of the main differential diagnostic criteria between LyP and PLEVA. However, similar to our patient, cases of a unique CD30+ PLEVA variant have been published in case reports and series. Although some have suggested that the absence of large CD30 (+) cells in the dermis may point towards a histologic diagnosis of PLEVA, the distinction between PLEVA and LyP in some cases is difficult, and the diagnosis may require extensive clinicopathologic correlation and follow-up [7,8].

Overall, PLEVA is very difficult to treat because of its unknown etiology and unpredictable course. Currently, there is no standard treatment for this condition, but a combination therapy is frequently considered the best approach [21]. Treatment options include phototherapy, oral antibiotics including macrolides and tetracyclines, topical corticosteroids, and antihistamines [21,22]. Azithromycin has been proven as a valid treatment and effective alternative when patients are unresponsive to the first line of treatment or when phototherapy is unavailable [23]. Systemic medications such as corticosteroids, methotrexate, cyclosporine, and retinoids may be warranted in severe manifestations of PLEVA unresponsive to conventional treatment [21,24].

4. Conclusions

We report an atypical case of PLEVA presenting as a complication of a COVID-19 infection. While histologically typical features were present, unusual features masking more typical histologic findings included the presence of a predominantly intraepider-
nal CD30+ infiltrate and a positive clonal TCR−γ gene rearrangement study. Similar findings have been seen in association with other virally induced cases of PLEVA. In this patient, the clinicopathologic correlation and response to treatment was paramount in confirming the diagnosis of PLEVA. Awareness of these reactions following a COVID-19 infection, accompanied by a comprehensive histopathologic evaluation of skin biopsies, should be completed to determine if PLEVA is directly related or not to the infection. The current level of evidence on this association is limited and based solely on case reports and case series. Further studies with systematic dermatological examination of patients with proven COVID-19 are needed to establish a formal association between infection and the development of PLEVA.

**Author Contributions:** Conceptualization, H.D.L.G., E.S., M.R.S., C.B.; and N.A.V.; investigation, H.D.L.G., E.S., M.R.S.; writing—original draft preparation, H.D.L.G. and E.S.; writing—review and editing, H.D.L.G., E.S., C.B and N.A.V. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Conflicts of Interest:** The authors have no relevant disclosure or conflict of interest to report relevant to this article.

**References**

1. Bowers, S.; Warshaw, E.M. Pityriasis lichenoides and its subtypes. *J. Am. Acad. Dermatol.* 2006, 55, 557–572. [CrossRef] [PubMed]
2. Fernandes, N.F.; Rozdeba, P.; Schwartz, R.A.; Kihiczak, G.; Lambert, W.C. Pityriasis lichenoides et varioliformis acuta: A disease spectrum. *Int. J. Dermatol.* 2010, 49, 257–261. [CrossRef] [PubMed]
3. Khachemoune, A.; Blyumin, M.L. Pityriasis Lichenoides. *Am. J. Clin. Dermatol.* 2007, 8, 29–36. [CrossRef] [PubMed]
4. Herron, M.D.; Bohnsack, J.F.; Vanderhooft, S.L. Septic, CD-30 Positive Ulceronecrotic Pityriasis Lichenoides et Varioliformis Acuta. *Pediatr. Dermatol.* 2005, 22, 360–365. [CrossRef]
5. Kempf, W.; Kazakov, D.V.; Palmedo, G.; Fraitag, S.; Schaerer, L.; Kutzner, H. Pityriasis Lichenoides et Varioliformis Acuta With Numerous CD30+ Cells. *Am. J. Surg. Pathol.* 2012, 36, 1021–1029. [CrossRef]
6. Borra, T.; Custrin, A.; Saggini, A.; Fink-Puches, R.; Cota, C.; Vermi, W.; Facchetti, F.; Cerroni, L. Pityriasis Lichenoides, Atypical Pityriasis Lichenoides, and Related Conditions. *Am. J. Surg. Pathol.* 2018, 42, 1101–1112. [CrossRef]
7. Kim, J.E.; Yun, W.J.; Mun, S.K.; Yoon, G.S.; Huh, J.; Choi, J.H.; Chang, S. Pityriasis lichenoides et varioliformis acuta and pityriasis lichenoides chronica: Comparison of lesional T-cell subsets and investigation of viral associations. *J. Cutan. Pathol.* 2011, 38, 649–656. [CrossRef]
8. Dereure, O.; Levi, E.; Kadin, M.E. T-Cell Clonality in Pityriasis Lichenoides et Varioliformis Acuta. *Arch. Dermatol.* 2000, 136, 1483–1486. [CrossRef]
9. Gianotti, R.; Restano, L.; Cutrone, M.; Colonna, C.; Fellegara, G.; Debernardi, I.; Boggio, F.; Del Gobbo, A.; Monzani, N.A.; Tripodo, C.; et al. Papulo-purpuric dermatitis of childhood: A distinct PLEVA-like eruption associated to SARS-CoV-2 infection. Clinical, histopathological and immunohistochemical study of 10 cases. *Pediatr. Dermatol.* 2021, 38, 1185–1190. [CrossRef]
10. Durusu, I.N.; Gurel, G.; Tokyol, C. Un caso de pitiriasis liquenoide crónica en una paciente infectada por COVID-19. *Actas Dermosifiliogr* 2021. [CrossRef]
11. Palmén, J.; Lepistö, M.; Talve, L.; Hieta, N. Pityriasis lichenoides et varioliformis acuta following COVID-19 mRNA vaccination. *J. Eur. Acad. Dermatol. Venereol.* 2022, 36, e327–e328. [CrossRef] [PubMed]
12. Semincola, A.; Dybala, A.; Gomes, V.; Maddalena, P.; Adotti, F.; Gomis, M.; Muharremi, R.; Fino, P.; Del Duca, E.; Grieco, T. Lymphomatoid drug reaction developed after BNT162b2 (Comirnaty) COVID-19 vaccine manifesting as pityriasis lichenoides et varioliformis acuta-like eruption. *J. Eur. Acad. Dermatol. Venereol.* 2011, 35, e15445. [CrossRef] [PubMed]
13. Dawoud, N.M.; Aslam, H.; Ali, J.M.; Dawoud, M.M. The first case report of Pityriasis lichenoides chronica following COVID-19 mRNA vaccination. *Dermatol. Ther.* 2022, 35, e15445. [CrossRef] [PubMed]
14. Sechi, A.; Pierobon, E.; Pezzolo, E.; Gemori, L.; Trevisan, G.; Zardo, D.; Riva, G.; Mondino, S.; Baldi, M. Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: Unravelling a possible common trigger, the COVID-19 vaccine. *Clin. Exp. Dermatol.* 2021, 47, 437–440. [CrossRef]
15. LeWitt, T.; Chang, C.; Manton, J.; Sergeyenko, A.; Tan, T.; Sigal, A.; Zhou, X.; ; Guitart, J. Rare lymphomatoid reactions following SARS-CoV-2 vaccination. *JAMA Dermatol.* 2022, 158, 26–30. [CrossRef] [PubMed]
16. Mäkilä, T.; Jeskanen, L.; Butina, M.; Harjama, L.; Ranki, A.; Mäkönen, T.; Kluger, N. Pityriasis lichenoides et varioliformis acuta after SARS-CoV-2 infection and relapse after vaccination. *J. Eur. Acad. Dermatol. Venereol.* 2022, 36, e431–e433. [CrossRef]
17. Filippi, F.; Baraldi, C.; Zinzani, P.; Casadei, B.; Pileri, A. A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford–AstraZeneca COVID-19 vaccine. *J. Eur. Acad. Dermatol. Venereol.* 2022. [CrossRef]

18. Vonderheid, E.C.; Kadin, M.E.; Telang, G.H. Commentary about papular mycosis fungoides, lymphomatoid papulosis and lymphomatoid pityriasis lichenoides: More similarities than differences. *J. Cutan. Pathol.* 2015, 43, 303–312. [CrossRef]

19. Moy, A.; Sun, J.; Ma, S.; Seminario-Vidal, L. Lymphomatoid Papulosis and Other Lymphoma-Like Diseases. *Dermatol. Clin.* 2019, 37, 471–482. [CrossRef]

20. Nieto-Benito, L.M.; de la Torre-Ruiz, E.H.; Balaguer-Franch, I.; Rosell-Díaz, M.; Mateos-Mayo, A.; Herrero-Sánchez, A.; Lacasta-Plasín, C.; García-Piqueras, P.; Barchino-Ortiz, L.; Bergón-Sendín, M.; et al. Histopathological findings in COVID-19-induced cutaneous lesions. Clinicopathological correlation of SARS-CoV-19 dermatologic patterns: Review of the literature. *Australas. J. Dermatol.* 2020, 62, e98–e101. [CrossRef]

21. Bellinato, F.; Maurelli, M.; Gisondi, P.; Girolomoni, G. A systematic review of treatments for pityriasis lichenoides. *J. Eur. Acad. Dermatol. Venereol.* 2019, 33, 2039–2049. [CrossRef] [PubMed]

22. Di Costanzo, L.; Balato, N.; La Bella, S.; Balato, A. Successful association in the treatment of pityriasis lichenoides et varioliformis acuta. *J. Eur. Acad. Dermatol. Venereol.* 2009, 23, 971–972. [CrossRef] [PubMed]

23. Skinner, R.B.; Levy, A.L. Rapid resolution of pityriasis lichenoides et varioliformis acuta with azithromycin. *J. Am. Acad. Dermatol.* 2008, 58, 524–525. [CrossRef] [PubMed]

24. Simon, D.; Boudny, C.; Nievergelt, H.; Simon, H.-U.; Braathen, L. Successful treatment of pityriasis lichenoides with topical tacrolimus. *Br. J. Dermatol.* 2004, 150, 1033–1035. [CrossRef]